News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for December 2025 Michael O'Riordan December 29, 2025
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for November 2024 Shelley Wood December 03, 2024
News Daily News DOAC Don’ts: New Review Clarifies When Not to Use Direct Oral Anticoagulants Shelley Wood January 17, 2024
News Conference News ESC 2023 ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients L.A. McKeown August 30, 2023
News Daily News Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest Michael O'Riordan October 20, 2022
Presentation TCT 2022 Anticoagulation Strategies in High-Risk PE: Are DOACs Enough? When Do We Switch? Presenter: Teresa Carman September 19, 2022
News Opinion Editor's Corner ESC 2022 What’s Going to Be Hot at ESC 2022? Shelley Wood August 22, 2022
News Daily News No Increased Bleeding With Alteplase in Stroke Patients on DOACs: Registry Data Yael L. Maxwell February 15, 2022
News Daily News Rivaroxaban Again Linked to More Bleeding vs Other DOACs Caitlin E. Cox October 11, 2021
News Daily News Long-term Anticoagulation After Unprovoked VTE: New Insights Shelley Wood September 13, 2021
News Opinion Editor's Corner ESC 2021 ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress Shelley Wood August 19, 2021
News Daily News Rivaroxaban May Yet Protect After a Hospital Stay: MARINER Caitlin E. Cox June 25, 2020
News Conference News ACC 2020 PRONOMOS: Rivaroxaban Beats Enoxaparin for Preventing VTE After Orthopedic Surgery Yael L. Maxwell March 31, 2020
News Daily News In Case of Emergency: Don’t Rely on ‘Normal’ Range Assays With DOACs Shelley Wood August 10, 2017